

15. **Pittet JF**, Lee H, Pespeni M, *et al.* Stress-induced inhibition of the NF-kappaB signaling pathway results from the insolubilization of the I-kappaB kinase complex following its dissociation from heat shock protein 90. *J Immunol* 2005;**174**:384–94.
16. **Dumler I**, Weis A, Mayboroda OA, *et al.* The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. *J Biol Chem* 1998;**273**:315–21.
17. **Kim HY**, Park EJ, Joe EH, *et al.* Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. *J Immunol* 2003;**171**:6072–9.
18. **Shah M**, Patel K, Fried VA, *et al.* Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. *J Biol Chem* 2002;**277**:45662–9.
19. **Fasbender A**, Lee JH, Walters RW, *et al.* Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. *J Clin Invest* 1998;**102**:184–93.
20. **Blanchette J**, Jaramillo M, Olivier M. Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. *Immunology* 2003;**108**:513–22.
21. **Zhang H**, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. *J Mol Med* 2004;**82**:488–99.
22. **Kamal A**, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. *Trends Mol Med* 2004;**10**:283–90.
23. **Pratt WB**, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. *Exp Biol Med (Maywood)* 2003;**228**:111–33.
24. **Yoshida M**, Xia Y. Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. *J Biol Chem* 2003;**278**:36953–8.
25. **Kiang JG**, Bowman PD, Wu BW, *et al.* Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70. *J Appl Physiol* 2004;**97**:564–9.
26. **Lau SS**, Griffin TM, Mestral R. Protection against endotoxemia by HSP70 in rodent cardiomyocytes. *Am J Physiol Heart Circ Physiol* 2000;**278**:H1439–45.
27. **Murphy P**, Sharp A, Shin J, *et al.* Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. *J Neurosci Res* 2002;**67**:461–70.
28. **Yeo M**, Park HK, Kim DK, *et al.* Restoration of heat shock protein70 suppresses gastric mucosal inducible nitric oxide synthase expression induced by *Helicobacter pylori*. *Proteomics* 2004;**4**:3335–42.
29. **Zhu S**, Ware LB, Geiser T, *et al.* Increased levels of nitrate and surfactant protein a nitration in the pulmonary edema fluid of patients with acute lung injury. *Am J Respir Crit Care Med* 2001;**163**:166–72.
30. **Hiratsuka M**, Yano M, Mora BN, *et al.* Heat shock pretreatment protects pulmonary isografts from subsequent ischemia-reperfusion injury. *J Heart Lung Transplant* 1998;**17**:1238–46.
31. **Lee H**, Pespeni M, Roux J, *et al.* HO-1 induction restores c-AMP-dependent lung epithelial fluid transport following severe hemorrhage in rats. *FASEB J* 2005;**19**:287–9.
32. **Sausville EA**, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. *Curr Cancer Drug Targets* 2003;**3**:377–83.

Pulmonary puzzle

ANSWER

From question on page 309

The major abnormalities shown in the CT and bronchoscopic images are nodularity and plaques on the anterolateral walls of the trachea and main bronchi. This is caused by tracheobronchopathia osteochondroplastica (TO). First described by Samuel Wilks in 1857,¹ it is a rare benign condition of unknown aetiology observed in about 0.1% of bronchoscopies.² A diagnosis of TO is suggested from characteristic sessile submucosal cartilaginous or bony nodules enlarging and protruding into the lumina of the anterior and lateral walls of the lower trachea and upper main bronchi.³ The posterior membranous portion is usually spared. Other causes of tracheobronchial irregularity include malignancy, amyloidosis, endobronchial sarcoidosis, Wegener granulomatosis and calcifying lesions of tuberculosis. Therefore, if endobronchial biopsy is possible, abnormally distributed mineralisation usually confirms the diagnosis. Most patients are asymptomatic or have a mild cough or haemoptysis requiring occasional courses of antibiotics or inhalers.³ Indeed, this patient had evidence on the CT scan (not shown) of a 'tree-in-bud' pattern of shadowing in the left lower lobe suggestive of an infective process, which can in itself cause haemoptysis. Large protrusions may cause retention pneumonias or severe dyspnoea from luminal obstruction. Therapeutic options include stenting, debulking with cryotherapy, surgical resection or laser photovaporisation.²

In normal subjects the bronchial basement membrane autofluoresces with a regular fine cross-hatching structure

under probe-based confocal laser endomicroscopy (pCLE) imaging; this regular pattern is destroyed in neoplasia and is possibly also disrupted in benign conditions.⁴ pCLE imaging of the nodular excrescences in this patient showed a mottled brightly autofluorescing submucosa but without any evidence of the cross-hatched healthy basement membrane. Some clinicians challenge the need to attempt tissue biopsy of certain benign lung conditions such as presumed TO; in the future, optical biopsy techniques such as pCLE may avoid this dilemma.

While this patient still has a dry cough, his haemoptysis was successfully treated with a course of oral ciprofloxacin and prednisolone. Together with his chronic obstructive pulmonary disease, his TO symptoms will be monitored and treated accordingly.

Thorax 2010;**65**:353. doi:10.1136/thx.2009.129890a

REFERENCES

1. **Wilks S**. Ossific deposits in the larynx, trachea and bronchi. *Trans Pathol Soc London* 1857;**8**:88.
2. **Jabbardarjani HR**, Radpey B, Kharabian S, *et al.* Tracheobronchopathia osteochondroplastica: presentation of ten cases and review of the literature. *Lung* 2008;**186**:293–7.
3. **Leske V**, Lazor R, Coetmeur D, *et al.* Tracheobronchopathia osteochondroplastica: a study of 41 patients. *Medicine (Baltimore)* 2001;**80**:378–90.
4. **Thiberville L**, Moreno-Swirc S, Vercauteren T, *et al.* In vivo imaging of the bronchial wall microstructure using fibered confocal fluorescence microscopy. *Am J Respir Crit Care Med* 2007;**175**:22–31.